These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18669161)

  • 41. Colorectal tumor vascularity: quantitative assessment with multidetector CT--do tumor perfusion measurements reflect angiogenesis?
    Goh V; Halligan S; Daley F; Wellsted DM; Guenther T; Bartram CI
    Radiology; 2008 Nov; 249(2):510-7. PubMed ID: 18812560
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CD 10 expression intensity in various grades and stages of urothelial carcinoma of urinary bladder.
    Atique M; Abbasi MS; Jamal S; Khadim MT; Akhtar F; Jamal N
    J Coll Physicians Surg Pak; 2014 May; 24(5):351-5. PubMed ID: 24848395
    [TBL] [Abstract][Full Text] [Related]  

  • 43. p53 and microvessel density in primary resection specimens of superficial bladder cancer.
    Reiher F; Ozer O; Pins M; Jovanovic BD; Eggener S; Campbell SC
    J Urol; 2002 Mar; 167(3):1469-74. PubMed ID: 11832772
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion.
    Brimo F; Wu C; Zeizafoun N; Tanguay S; Aprikian A; Mansure JJ; Kassouf W
    Hum Pathol; 2013 Jan; 44(1):95-102. PubMed ID: 22939956
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A prospective pilot evaluation of urinary and immunohistochemical markers as predictors of clinical stage of urothelial carcinoma of the bladder.
    Krupski T; Moskaluk C; Boyd JC; Theodorescu D
    BJU Int; 2000 Jun; 85(9):1027-32. PubMed ID: 10848689
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence.
    Hu Z; Mudaliar K; Quek ML; Paner GP; Barkan GA
    Ann Diagn Pathol; 2014 Apr; 18(2):49-52. PubMed ID: 24370460
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hypoxia contributes to development of recurrent endometrial carcinoma.
    Pijnenborg JM; Wijnakker M; Hagelstein J; Delvoux B; Groothuis PG
    Int J Gynecol Cancer; 2007; 17(4):897-904. PubMed ID: 17359291
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Qualitative and quantitative analysis of angiogenetic factors in transitional cell bladder carcinoma: relationship with clinical course at 10 years follow-up.
    Bartoletti R; Cai T; Nesi G; Sardi I; Rizzo M
    Oncol Rep; 2005 Jul; 14(1):251-5. PubMed ID: 15944797
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
    Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D.
    Miyata Y; Kanda S; Ohba K; Nomata K; Hayashida Y; Eguchi J; Hayashi T; Kanetake H
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):800-6. PubMed ID: 16467091
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proliferation and maturation of intratumoral blood vessels in women with malignant ovarian tumors assessed with cancer stem cells marker nestin and platelet derived growth factor PDGF-B.
    Czekierdowska S; Stachowicz N; Chróściel M; Czekierdowski A
    Ginekol Pol; 2017; 88(3):120-128. PubMed ID: 28397199
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer.
    Onita T; Ji PG; Xuan JW; Sakai H; Kanetake H; Maxwell PH; Fong GH; Gabril MY; Moussa M; Chin JL
    Clin Cancer Res; 2002 Feb; 8(2):471-80. PubMed ID: 11839666
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
    Mhawech P; Herrmann F; Coassin M; Guillou L; Iselin CE
    Cancer; 2003 Oct; 98(8):1649-57. PubMed ID: 14534881
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma.
    Mizutani Y; Wada H; Fukushima M; Yoshida O; Nakanishi H; Li YN; Miki T
    Cancer; 2004 Feb; 100(4):723-31. PubMed ID: 14770427
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
    Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
    Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic relevance of micro-vessel density in cancer of the urinary bladder.
    Chaudhary R; Bromley M; Clarke NW; Betts CD; Barnard RJ; Ryder WD; Kumar S
    Anticancer Res; 1999; 19(4C):3479-84. PubMed ID: 10629639
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
    Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target.
    Crew JP; O'Brien TS; Harris AL
    Cancer Metastasis Rev; 1996 Jun; 15(2):221-30. PubMed ID: 8842494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer.
    Goddard JC; Sutton CD; Furness PN; O'Byrne KJ; Kockelbergh RC
    Clin Cancer Res; 2003 Jul; 9(7):2583-6. PubMed ID: 12855634
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Immunohistochemical analysis of expression of angiogenic factors and tumor angiogenesis in superficial bladder cancer].
    Ogura Y; Sato K; Kato T; Saito K; Enomoto K
    Nihon Hinyokika Gakkai Zasshi; 1998 May; 89(5):529-37. PubMed ID: 9642990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.